Vaccinex, Inc. (NASDAQ:VCNX) Short Interest Update

Vaccinex, Inc. (NASDAQ:VCNX) was the target of a large growth in short interest during the month of June. As of June 15th, there was short interest totalling 20,100 shares, a growth of 118.5% from the May 31st total of 9,200 shares. Based on an average daily trading volume, of 18,200 shares, the days-to-cover ratio is presently 1.1 days. Approximately 2.6% of the shares of the company are sold short.

Vaccinex Stock Up 5.0 %

Vaccinex stock traded up $0.31 on Friday, reaching $6.49. 7,230 shares of the stock were exchanged, compared to its average volume of 40,662. Vaccinex has a twelve month low of $4.43 and a twelve month high of $83.56. The firm has a fifty day moving average price of $6.00 and a two-hundred day moving average price of $7.49.

Vaccinex (NASDAQ:VCNX) last released its earnings results on Wednesday, May 15th. The company reported ($2.94) earnings per share (EPS) for the quarter. The business had revenue of $0.10 million during the quarter.

Institutional Investors Weigh In On Vaccinex

A hedge fund recently raised its stake in Vaccinex stock. Worth Venture Partners LLC grew its stake in Vaccinex, Inc. (NASDAQ:VCNX) by 417.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 717,559 shares of the company’s stock after purchasing an additional 578,764 shares during the period. Worth Venture Partners LLC owned about 16.31% of Vaccinex worth $811,000 as of its most recent SEC filing. Institutional investors own 50.11% of the company’s stock.

Vaccinex Company Profile

Vaccinex, Inc, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.